P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.

• Michael Gundesen,
• Fredrik Schjesvold,
• Annette Vangsted,
• Carsten Helleberg,
• Einar Haukås,
• Trine Silkjær,
• Elena Todorescu,
• Bo Amdi Jensen,
• Tobias S. Slørdahl,
• Jon Thor Asmussen,
• Hareth Nahi,
• Anders Waage,
• Niels Abildgaard,
• Thomas Lund

Affiliations

Michael Gundesen

1 Odense University Hospital, Department of Hematology

Fredrik Schjesvold

2 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway

Annette Vangsted

3 Department of Hematology, Rigshospitalet, Copenhagen, Denmark

Carsten Helleberg

3 Department of Hematology, Rigshospitalet, Copenhagen, Denmark

Einar Haukås

4 Department of Blood and cancer diseases, Stavanger University Hospital, Norway

Trine Silkjær

5 Department of Hematology, Aarhus University Hospital, Denmark

Elena Todorescu

6 Department of Hematology Aalborg University Hospital, Denmark

Bo Amdi Jensen

7 Department of Hematology, Zealand University Hospital, Denmark

Tobias S. Slørdahl

8 Department of Hematology, St. Olavs Hospital - Trondheim University Hospital

Jon Thor Asmussen

9 Odense University Hospital, Department of radiology, Denmark

Hareth Nahi

10 Karolinska Institutet, Sweden

Anders Waage

8 Department of Hematology, St. Olavs Hospital - Trondheim University Hospital

Niels Abildgaard

11 Department of Clinical Research, University of Southern Denmark, Denmark, Department of hematology

Thomas Lund

12 Odense University Hospital, Department of Clinical Research, University of Southern Denmark, Denmark